MedKoo Cat#: 598508 | Name: Pradigastat sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pradigastat, also known as LCQ-908 and ANJ-908, is potent and oral DGAT1 inhibitor. Pradigastat is being developed for the treatment of familial chylomicronemia syndrome. Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting in fasting chylomicronemia and severe hypertriglyceridemia. Inhibition of diacylglycerol acyltransferase 1 (DGAT1), which mediates chylomicron triglyceride (TG) synthesis, is an attractive strategy to reduce TG levels in FCS .

Chemical Structure

Pradigastat sodium
Pradigastat sodium
CAS#956136-98-4 (sodium)

Theoretical Analysis

MedKoo Cat#: 598508

Name: Pradigastat sodium

CAS#: 956136-98-4 (sodium)

Chemical Formula: C25H23F3N3NaO2

Exact Mass: 0.0000

Molecular Weight: 477.46

Elemental Analysis: C, 62.89; H, 4.86; F, 11.94; N, 8.80; Na, 4.81; O, 6.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Pradigastat sodium; LCQ 908ABA; LCQ-908ABA; LCQ908ABA; LCQ-908; LCQ908; LCQ 908; ANJ-908; ANJ 908; ANJ908
IUPAC/Chemical Name
sodium 2-((1r,4r)-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexyl)acetate
InChi Key
MUZRGKSNUTWRAF-BHQIMSFRSA-M
InChi Code
InChI=1S/C25H24F3N3O2.Na/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33;/h5-12,14-17,31H,1-4,13H2,(H,32,33);/q;+1/p-1/t16-,17-;
SMILES Code
O=C([O-])C[C@H](CC1)CC[C@@H]1c2ccc(c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 477.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kulmatycki K, Hanna I, Meyers D, Salunke A, Movva A, Majumdar T, Natrillo A, Vapurcuyan A, Rebello S, Sunkara G, Chen J. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. Int J Clin Pharmacol Ther. 2015 May;53(5):345-55. doi: 10.5414/CP202275. PubMed PMID: 25740267.